Archived Insight | April 12, 2022

Well-Funded Multiemployer Pension Plans Improved Benefits

Financially troubled multiemployer pension plans continue to be the focus of attention, particularly now that they may be eligible to apply for PBGC special financial assistance (SFA). Despite that understandable spotlight, it’s important to keep in mind that most plans are not in critical and declining status (i.e., facing insolvency).

In fact, many strong multiemployer pension plans have improved benefits over the past three years.

To see a snapshot of data from our latest survey, download an infographic.

Get the Infographic

Well-Funded Multiemployer Pension Plans Improved Benefits Download Now

Is your board considering making benefit improvements?

We can help you evaluate your plan’s financial health and the affordability of benefit improvements. Let's Talk.

Segal’s Winter 2022 Survey of Plans’ Zone Status

The 283 plans included in this survey are those with plan years that range from January 1 to July 1.

As a group, these plans have more than $215 billion in assets, provide benefits to just over 3.5 million participants and represent approximately one-third of all participants in multiemployer plans.

The 2021 zone-status certifications for the plans in the survey reflect investment performance before the current market volatility and geopolitical uncertainty.

 

See more insights

Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.
Focused Business Woman Working On Laptop Computer Reading

Many Retirement Plans Must Be Amended by December 31, 2026

Learn which retirement plans must be amended by December 31, 2026 and how SECURE Act discretionary and required amendments differ.
Man Self Injecting GLP 1 Weight Loss Medication Pen At Home

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

Segal’s SHAPE data shows how rising GLP-1 use coincided with declines in insulin, Metformin and DPP-4 inhibitor use.

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.